Axion BioSystems is a US-based life sciences tools company focused on advanced live-cell assay systems and a portfolio company of Summa Equity. Axion BioSystems has acquired CytoSMART, a Dutch biotechnology company focused on kinetic live-cell imaging analysis. The acquisition of CytoSMART puts Axion in a position for significant expansion in the fields of stem cell research, immuno-oncology, cell-based therapies, and drug discovery. We advised CytoSMART and its selling shareholders, including Holland Capital, BOM and ECFG (Eindhoven Corporate Finance Group), on this transaction.